Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio Sells China Rights for Radioenhanced Drug to Janssen for $30 Million

publication date: Dec 26, 2023

LianBio, a Shanghai-Princeton in-licensing biotech, has sold greater China rights for a radioenhancer to Janssen Pharma in a $30 million agreement. LianBio will receive $25 million upfront and up to another $5 million in sales milestones. NBTXR3 is a novel first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. In 2022, LianBio acquired the rights from Nanobiotix, a Paris oncology company. Janssen acquired global rights (ex-China) to the radioenhancer earlier this year, paying $30 million upfront, plus other contingent payments. More details....

Stock Symbol: (Nasdaq: LIAN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital